Limits...
TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances.

Zhang W, Shao ZH, Fu R, Wang HQ, Li LJ, Wang J, Qu W, Liang Y, Wang GJ, Wang XM, Wu Y, Liu H, Song J, Guan J, Xing LM - Cancer Biol Med (2012)

Bottom Line: The expression of TET2 mRNA in BMMNC was down-regulated in MDS patients compared with the donor group [(0.41±0.28)% vs. (1.07±0.56)%] (P<0.001).The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group.The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased, which might be useful as an important parameter for the evaluation of MDS clone burden.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.

ABSTRACT

Objective: To investigate the expression of TET2 mRNA and protein in the bone marrow mononuclear cells (BMMNC) of patients with myelodysplastic syndrome (MDS) and its clinical significance.

Methods: The expression of TET2 mRNA and protein in bone marrow mononuclear cells (BMMNC) of 32 patients with MDS and 20 healthy donors was examined by qPCR and Western blot.

Results: The expression of TET2 mRNA in BMMNC was down-regulated in MDS patients compared with the donor group [(0.41±0.28)% vs. (1.07±0.56)%] (P<0.001). Compared with lower expression group (TET2<0.4) [(6.53±6.17)%], patients with higher expression of TET2 (≥0.4) presented significantly lower proportion of bone marrow blasts [(1.21±1.56)%] (P<0.05). The expression of TET2 mRNA in BMMNC of MDS patients was inversely correlated with malignant clone burden (r=-0.398, P<0.05) and IPSS (r=-0.412, P<0.05). The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group.

Conclusions: The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased, which might be useful as an important parameter for the evaluation of MDS clone burden.

No MeSH data available.


Related in: MedlinePlus

Expression of TET2 mRNA in the BMMNC of patients with different MDS types. * comparison between RA/RARS and RAEB patients, P<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3643638&req=5

f1: Expression of TET2 mRNA in the BMMNC of patients with different MDS types. * comparison between RA/RARS and RAEB patients, P<0.05.

Mentions: The average expression of TET2 mRNA was 0.63 (0.28-1.01) in RA and RAS patients, 0.39 (0.09-1.23) in RCMD patients, and 0.27 (0.11-0.91) in RAEB patients. There was significant difference between RA/RAS and RAEB groups (P<0.05, Figure 1).


TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances.

Zhang W, Shao ZH, Fu R, Wang HQ, Li LJ, Wang J, Qu W, Liang Y, Wang GJ, Wang XM, Wu Y, Liu H, Song J, Guan J, Xing LM - Cancer Biol Med (2012)

Expression of TET2 mRNA in the BMMNC of patients with different MDS types. * comparison between RA/RARS and RAEB patients, P<0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3643638&req=5

f1: Expression of TET2 mRNA in the BMMNC of patients with different MDS types. * comparison between RA/RARS and RAEB patients, P<0.05.
Mentions: The average expression of TET2 mRNA was 0.63 (0.28-1.01) in RA and RAS patients, 0.39 (0.09-1.23) in RCMD patients, and 0.27 (0.11-0.91) in RAEB patients. There was significant difference between RA/RAS and RAEB groups (P<0.05, Figure 1).

Bottom Line: The expression of TET2 mRNA in BMMNC was down-regulated in MDS patients compared with the donor group [(0.41±0.28)% vs. (1.07±0.56)%] (P<0.001).The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group.The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased, which might be useful as an important parameter for the evaluation of MDS clone burden.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.

ABSTRACT

Objective: To investigate the expression of TET2 mRNA and protein in the bone marrow mononuclear cells (BMMNC) of patients with myelodysplastic syndrome (MDS) and its clinical significance.

Methods: The expression of TET2 mRNA and protein in bone marrow mononuclear cells (BMMNC) of 32 patients with MDS and 20 healthy donors was examined by qPCR and Western blot.

Results: The expression of TET2 mRNA in BMMNC was down-regulated in MDS patients compared with the donor group [(0.41±0.28)% vs. (1.07±0.56)%] (P<0.001). Compared with lower expression group (TET2<0.4) [(6.53±6.17)%], patients with higher expression of TET2 (≥0.4) presented significantly lower proportion of bone marrow blasts [(1.21±1.56)%] (P<0.05). The expression of TET2 mRNA in BMMNC of MDS patients was inversely correlated with malignant clone burden (r=-0.398, P<0.05) and IPSS (r=-0.412, P<0.05). The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group.

Conclusions: The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased, which might be useful as an important parameter for the evaluation of MDS clone burden.

No MeSH data available.


Related in: MedlinePlus